Celltrion Pharm Inc (068760) — Capital Reinvestment Ratio
Latest as of September 2025:
0.10x
Celltrion Pharm Inc (068760) has a Capital Reinvestment Ratio of 0.10x as of September 2025, meaning it reinvests 0% of its operating cash flow (₩23.44 Billion) in capital expenditures (₩2.27 Billion). See free cash flow generation of Celltrion Pharm Inc to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.10x
Capex / Operating Cash Flow
Operating Cash Flow
₩23.44 Billion
KRW
Capital Expenditures
₩2.27 Billion
KRW
Data as of
Sep 2025
Most recent filing
Celltrion Pharm Inc Capital Reinvestment Ratio (2014–2024)
This chart tracks Celltrion Pharm Inc's Capital Reinvestment Ratio across 8 annual periods.
Annual Capital Reinvestment Ratio for Celltrion Pharm Inc (2014–2024)
Year-by-year Capital Reinvestment Ratio for Celltrion Pharm Inc from 2014 to 2024. For live market cap and broader valuation context, see Celltrion Pharm Inc stock valuation.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.11x | ₩56.59 Billion | ₩5.98 Billion | ▼ -86.6% |
| 2023 | 0.79x | ₩8.76 Billion | ₩6.90 Billion | ▲ +487.0% |
| 2021 | 0.13x | ₩93.15 Billion | ₩12.50 Billion | ▼ -88.4% |
| 2020 | 1.16x | ₩36.25 Billion | ₩41.98 Billion | ▲ +5.8% |
| 2019 | 1.09x | ₩27.85 Billion | ₩30.49 Billion | ▲ +117.4% |
| 2018 | 0.50x | ₩14.31 Billion | ₩7.21 Billion | ▼ -85.4% |
| 2015 | 3.44x | ₩13.36 Billion | ₩45.97 Billion | ▲ +127.8% |
| 2014 | 1.51x | ₩17.33 Billion | ₩26.16 Billion | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow